Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

IntroductionBone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have dramatically changed the therapeutic landscape of NSCLC, little information is available on BMs from NSCLC treated with ICIs alone...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alberto Bongiovanni, Flavia Foca, Jessica Menis, Stefania Luigia Stucci, Fabrizio Artioli, Valentina Guadalupi, Maria Rosachiara Forcignanò, Manuela Fantini, Federica Recine, Laura Mercatali, Chiara Spadazzi, Marco Angelo Burgio, Valentina Fausti, Anna Miserocchi, Toni Ibrahim
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
immune checkpoint inhibitors
NSCLC
bone metastases
zoledronate
denosumab
lung cancer
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/efaf44bda0a24525b2e67623d8a9d899
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/efaf44bda0a24525b2e67623d8a9d899

Ejemplares similares